摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-氨基-N-异丙基苯磺酰胺 | 53668-35-2

中文名称
4-氨基-N-异丙基苯磺酰胺
中文别名
——
英文名称
sulfanilic acid N-(1-methylethyl) amide
英文别名
4-amino-N-isopropylbenzenesulfonamide;4-amino-N-(1-methylethyl)benzenesulfonamide;4-[(1-methylethylamino)sulfonyl]aniline;4-amino-N-isopropyl-benzenesulfonamide;4-Amino-benzolsulfonyl-isopropylamid;4-(N-Isopropylsulfamoyl)anilin;4-amino-N-propan-2-ylbenzenesulfonamide
4-氨基-N-异丙基苯磺酰胺化学式
CAS
53668-35-2
化学式
C9H14N2O2S
mdl
MFCD03753717
分子量
214.288
InChiKey
QYCULOSSKUXFNP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    115 °C
  • 沸点:
    370.4±44.0 °C(Predicted)
  • 密度:
    1.219±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    14
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.333
  • 拓扑面积:
    80.6
  • 氢给体数:
    2
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2935009090
  • 危险性防范说明:
    P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P362,P403+P233,P501
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    应存放在室温、密封、干燥、避光且在惰性气体环境中。

SDS

SDS:965fa58de836d361f111a09d677a97dc
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: N-Isopropyl 4-aminobenzenesulfonamide
Synonyms: 4-Amino-N-isopropylbenzenesulfonamide

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: N-Isopropyl 4-aminobenzenesulfonamide
CAS number: 53668-35-2

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H14N2O2S
Molecular weight: 214.3

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES<br/>[FR] DÉRIVÉS DE PYRIMIDONE À CYCLES FUSIONNÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B OU DE MALADIES INDUITES PAR LE VIRUS DE L'HÉPATITE B
    申请人:JANSSEN SCIENCES IRELAND UNLIMITED CO
    公开号:WO2020182990A1
    公开(公告)日:2020-09-17
    The present application relates to compounds according to Formula (I), pharmaceutical compositions comprising at least one of said compounds, their use as a medicament, and their use in treating chronic hepatitis B virus (HBV) infection. The disclosure further pertains to methods for preparing compounds according to Formula (I).
    本申请涉及按照式(I)的化合物,包括至少一种所述化合物的药物组合物,其作为药物的用途,以及其在治疗慢性乙型肝炎病毒(HBV)感染中的用途。该公开还涉及按照式(I)制备化合物的方法。
  • NOVEL TETRAHYDROQUINOLINE DERIVATIVES
    申请人:Feng Lichun
    公开号:US20120190677A1
    公开(公告)日:2012-07-26
    The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein R 1 to R 8 , A 1 to A 3 have the are as described herein and compositions including the compounds.
    本发明涉及公式(I)的化合物或其药学上可接受的盐或酯,其中R1至R8,A1至A3如本文所述,并包括该化合物的组合物。
  • Effect of Photodynamic Antibacterial Chemotherapy Combined with Antibiotics on Gram-Positive and Gram-Negative Bacteria
    作者:Yana Ilizirov、Andrei Formanovsky、Irina Mikhura、Yossi Paitan、Faina Nakonechny、Marina Nisnevitch
    DOI:10.3390/molecules23123152
    日期:——

    The well-known and rapidly growing phenomenon of bacterial resistance to antibiotics is caused by uncontrolled, excessive and inappropriate use of antibiotics. One of alternatives to antibiotics is Photodynamic Antibacterial Chemotherapy (PACT). In the present study, the effect of PACT using a photosensitizer Rose Bengal alone and in combination with antibiotics including methicillin and derivatives of sulfanilamide synthesized by us was tested against antibiotic-sensitive and antibiotic-resistant clinical isolates of Gram-positive S. aureus and Gram-negative P. aeruginosa. Antibiotic-sensitive and resistant strains of P. aeruginosa were eradicated by Rose Bengal under illumination and by sulfanilamide but were not inhibited by new sulfanilamide derivatives. No increase in sensitivity of P. aeruginosa cells to sulfanilamide was observed upon a combination of Rose Bengal and sulfanilamide under illumination. All tested S. aureus strains (MSSA and MRSA) were effectively inhibited by PACT. When treated with sub-MIC concentrations of Rose Bengal under illumination, the minimum inhibitory concentrations (MIC) of methicillin decreased significantly for MSSA and MRSA strains. In some cases, antibiotic sensitivity of resistant strains can be restored by combining antibiotics with PACT.

    广为人知且迅速增长的细菌对抗生素的抗性现象是由抗生素的无序、过度和不当使用引起的。抗生素的替代方案之一是光动力抗菌化疗(PACT)。在本研究中,使用光敏剂罗斯本加上抗生素(包括由我们合成的甲氧苄青霉素和磺胺类衍生物)的PACT对革兰氏阳性金黄色葡萄球菌和革兰氏阴性绿脓杆菌的抗生素敏感和抗生素耐药临床分离株进行了测试。罗斯本在照射下和磺胺类药物的作用下消灭了绿脓杆菌的抗生素敏感和耐药株,但新的磺胺类衍生物却无法抑制它们。在照射下,罗斯本与磺胺类药物的联合对绿脓杆菌细胞对磺胺类药物的敏感性没有增加。所有经过测试的金黄色葡萄球菌株(MSSA和MRSA)均被PACT有效抑制。在照射下用亚最小抑菌浓度的罗斯本处理时,对MSSA和MRSA株的甲氧苄青霉素的最小抑菌浓度(MIC)显著降低。在某些情况下,通过将抗生素与PACT结合可以恢复耐药株的抗生素敏感性。
  • An efficient and practical synthesis of 2,4-substituted pyrido[4,3-d]pyrimidin-5(6H)-ones
    作者:Xinrong Tian、Dominic P. Suarez、William Hoi Hong Li、Allison K. McSherry、Robert M. Sanchez、Michael L. Moore、Jeffrey M. Axten
    DOI:10.1016/j.tetlet.2019.151312
    日期:2019.12
    We describe an efficient synthesis of 2,4-substituted pyrido[4,3-d]pyrimidin-5(6H)-ones, which involves the acid-promoted cyclization of cyano enamine 15 to afford 2,4-bis-thiomethyl pyrido[4,3-d]pyrimidin-5(6H)-one 17 as a key intermediate. Selective displacement of the 4-methylthio group by a wide range of anilines followed by oxidation of the 2-methylthio group and subsquent substitution by amines
    我们描述了2,4-取代的吡啶并[4,3- d ]嘧啶-5(6 H)-ones的有效合成,其中涉及酸促成氰基烯胺15的环化反应,从而提供2,4-双-硫代甲基吡啶基并[4,3- d ]嘧啶-5(6 ħ) -酮17,为关键中间体。通过广泛的苯胺选择性置换4-甲硫基,然后氧化2-甲硫基并随后被胺取代,使得能够合成各种2,4-二取代的吡啶并[4,3- d ]嘧啶- 5(6 H)-个。
  • A new class of anti-HIV-1 agents targeted toward the nucleocapsid protein NCp7: The 2,2′-dithiobisbenzamides
    作者:John M. Domagala、John P. Bader、Rocco D. Gogliotti、Joseph P. Sanchez、Michael A. Stier、Yuntao Song、J.V.N. Vara Prasad、Peter J. Tummino、Jeffrey Scholten、Patricia Harvey、Tod Holler、Steve Gracheck、Donald Hupe、William G. Rice、Robert Schultz
    DOI:10.1016/s0968-0896(96)00269-6
    日期:1997.3
    for anti-HIV-1 activity, cytotoxicity, and their ability to extrude zinc from the zinc fingers for NCp7. The structure-activity relationships demonstrated that the ability to extrude zinc from NCp7 resided in the 2,2'-dithiobisbenzamide core structure. The 3,3' and the 4,4' isomers were inactive. While many analogs based upon the core structure retained the zinc extrusion activity, the best overall
    作为美国国家癌症研究所药物筛选计划的一部分,已经鉴定出了一类新的对人类免疫缺陷病毒HIV-1有活性的抗逆转录病毒药,并提出了HIV-1核衣壳蛋白NCp7作为抗病毒作用的靶标。2,2'-二硫代双-[4'-(氨磺酰基)苯甲酰苯胺](3x)和2,2'-二硫代双(5-乙酰氨基)苯甲酰胺(10)代表了原型铅结构。制备了各种2,2'-二硫代双苯甲酰胺,并测试了它们的抗HIV-1活性,细胞毒性以及从NCf7的锌指中挤出锌的能力。结构-活性关系表明,从NCp7挤出锌的能力存在于2,2'-二硫代双苯甲酰胺核心结构中。3,3'和4,4'异构体没有活性。虽然许多基于核心结构的类似物保留了锌的挤出活性,但只有在具有羧酸,羧酰胺或苯磺酰胺官能团的狭窄衍生物中才发现最佳的总体抗HIV-1活性。这些功能组与降低NCp7的抗病毒效力或活性相比,对于降低细胞毒性而言更为重要。所有具有抗病毒活性的化合物也从NCp7中挤出锌。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐